-
Am J Epidemiol: Sensitive screening methods early detection of lung cancer may lead to additional thyroid tumors.
Time of Update: 2020-08-24
We conducted a second analysis of the National Lung Screening Trial (registered 2002-2004), a randomized controlled trial that compared low-dose computerized fault scans (LDCT; n s 26,722) and chest X-ray photography (CXR; n s 26,732) to detect lung cancer to detect accidental findings related to thyroid cancer (ThCa).
-
Blood: Glucoderosterone enhances the anti-FRT3 mutant AML activity of FRT3 inhibitors.
Time of Update: 2020-08-24
through RNA sequencing and drug screening, Gebru and others found that the treatment of FRT3-ITD AML cells with the selective FRT3 inhibitor quizartinib increased the inflammatory gene of DTPs, thereby enhancing their sensitivity to anti-inflammatory glucoscosteroids.
-
Nature Sub-Journal: Tumor Escape? Blocking its secretion of steroids may slow tumor growth.
Time of Update: 2020-08-24
Recently, researchers from the Department of Pathology and MRC Cancer at the Wellcome Sanger Institute at the University of Cambridge found that immune T-cells from mouse skin and breast tumors secrete steroids, while blocking the production of such steroids can slow the growth of tumors in mice.
-
GENETICS: Genetic mutations in the scariest predators can suppress cancer! Or the "saviour" of future humans!
Time of Update: 2020-08-24
A recent study by scientists at Washington State University (WSU) and the Fred Hutchinson Cancer Research Center in Seattle found that a single genetic mutation in the kangaroo can lead to reduced growth of facial tumor disease (DFTD), providing new insights into the treatment of cancers such as prostate and colon cancer in humans.
-
Scientists have discovered a new drug target for pancreatic cancer, the PPP1R1B protein.
Time of Update: 2020-08-24
Dr Aindya Bagchi, associate professor of cancer initiation and maintenance at the Sanford Burnham Preby Institute for Medical Discovery and senior author of the study, said: "Our findings suggest that a protein called PPP1R1B is new to pancreatic cancer researchers and can drive tumor metastasis, which is the main cause of cancer death.
-
Blood: Kafazomi-Lynadamine-Disemisong combined stem cell transplant treatment for multiple myeloma.
Time of Update: 2020-08-24
Central point: KRd joint transplants extended for NDMM patients provide high-quality relief, with extended disease control time and controlled tolerance, rapid remission, but most patients need extended KRd treatment if optimal remission is required.
-
The application value of ring drugs in different malignant tumors.
Time of Update: 2020-08-24
Although some of the current new complementary treatment studies have been tried without tyrides, such as INR2-positive breast cancer, the dual-targeted drug combined with purple shirt drugs, but may be mainly targeted therapy effect, and does not fully reflect the role of chemotherapy.
-
Blood: Trib1 promotes AML progress by adjusting the transcription of Hoxa9.
Time of Update: 2020-08-24
Center point: Trib1 can affect Hoxa9 in myeloid leukemia by degrading C/EBP alpha and modifying Hoxa9-related super-enhancers; Erg is a key target for Trib1 and Hoxa9, responds to BRD4 inhibition, and plays a key role in leukemia.
-
Science Sub-Journal: Breast cancer can be detected in 1 hour! Portable cell analyzer accuracy of up to 100%!
Time of Update: 2020-08-24
to this end, an international team of researchers has designed an automated image cytometer system called CytoPAN, which can use samples obtained from fine needle punctures to accurately detect breast cancer and identify its sub-types within an hour, enabling rapid diagnosis of breast cancer.
-
Nat Cancer: Signatera ctDNA tests from Thenatera, a genetic testing company, have shown the ability to predict immunotherapy responses to advanced cancers.
Time of Update: 2020-08-24
in a Phase II study, researchers demonstrated that Natera's Signatera ctDNA analysis may help monitor whether patients with various cancers respond to immunotherapy.
researchers found that changes in early ctDNA levels during immunotherapy after six weeks of treatment could predict whether patients would benefit from the five groups of immunotherapy.
-
See how bulls use tumor immunity to reach the top of Nature.
Time of Update: 2020-08-24
Today, let's take stock of new findings on topics from solid tumors to blood cancers and even digital diagnosis, and see how cancer-immune bulls are using emerging platforms such as single-celled technology and digital spatial analysis to continue to ride the storm and dominate high-score journals such as Nature in 2020.
-
Opdivo and Yervoy significantly increase the survival rate of patients with thyoracic mesothelioma!
Time of Update: 2020-08-24
recent studies have shown that immunotherapy Opdivo (nivolumab) in combination with ipilimumab has improved survival rates in previously untreated patients with malignant thoracic mesothelioma (MPM).
CheckMate-743 trial showed that Opdivo combined with Yervoy significantly improved survival rates in patients with non-epiderm and epiderm MPM.
-
CheckMate-743 is the first and only Phase III clinical trial to demonstrate that first-line immunotherapy can improve the survival benefits of patients with malignant thoracic mesothelioma.
Time of Update: 2020-08-24
Note: There are currently no immuno-oncology drugs approved for the treatment of thoracic mesothelioma at Chinese mainland About CheckMate-743CheckMate -743 is an open-label, multi-center, randomized, Phase III clinical study designed to evaluate Compared to standard chemotherapy (Pemmytase combined cisplatin or capa) , Navoliu monoantigenated ipimu monotherapy was used in patients with previously untreated malignant thymus mesothelioma (MPM; n .605).
-
New endocrine therapy helps to standardize the management of prostate cancer mHSPC.
Time of Update: 2020-08-24
2. Accurate identification of mPC high-risk factors, timely and effective intervention in the mHSPC stage, is the key to the long-term benefits of mPC in Beijing, Shanghai and Guangzhou, a study showed that the new diagnosis of prostate cancer patients in China, 54% of patients have been diagnosed with distant metastasis (including bone and abdominal organ metastasis), about 38% of patients have developed to the mcrPC stage, equivalent to late stage.
-
Lancet Diabetes Endocrinol: Simple urine tests for more accurate detection of adrenal cancer are expected to be included in the guidelines.
Time of Update: 2020-08-24
A new study published recently in The Lancet Diabetes and Endocrinology found that simple urine testing of patients with adrenal lumps combined with routine imaging tests can help speed up diagnosis of adrenal cancer, improve patient prognosis, and reduce the need for invasive diagnostic techniques.
-
Eur Urol: Population-based queue study - Screening for prostate cancer from the age of 50-54.
Time of Update: 2020-08-24
17 years, regular PSA screening of men in their early 50s in Gothenburg more than tripled the risk of prostate cancer diagnosis compared to men not screened in Malmo (incidence was more than 2.56, 95% confidence interval (CI) 2.18,3 (0.02), but the risk of metastasis (IRR 0.43, 95% CI 0.22, 0.79) and prostate cancer death (IRR 0.29, 95% CI 0.11, 0.67) were significantly reduced.
-
Alert! Exposure to blue light at night increases the risk of colorectal cancer!
Time of Update: 2020-08-24
Previous studies have found a link between nighttime exposure to artificial light, especially blue light, and various adverse health effects, including sleep disorders, obesity, and an increased risk of various types of cancer, especially among night shift workers.
-
BMJ Blasts . . . After 22 years of follow-up, Chinese scholars have found that eating garlic for a long time can reduce the death rate from stomach cancer.
Time of Update: 2020-08-24
Although shandong intervention trials have shown that Helicobacter pylori therapy has a potential role in the prevention of stomach cancer, further follow-up is needed to determine whether it will lead to a significant reduction in gastric cancer mortality over a longer period of time.
-
Clin Cancer Res: The effect of small doses of metformin on the immune microennourage of esophageal cancer tumors.
Time of Update: 2020-08-24
In a Phase II clinical trial of low-dose metformin (250 mg/day) therapy, the researchers analyzed samples of esophageal squamous cancer before and after the paired treatment to assess the activity of direct resistance to ESCC and TIME reprogramming.
-
Another 叒 in the Nature sub-issue! Four-stranded DNA structures have been found in breast cancer cells for the first time.
Time of Update: 2020-08-24
In 2013, researchers led by Shankar Balasubramanian, also from the University of Cambridge, published an article in the journal Nature Chemistry, using strong evidence for the first time that four-stranded DNA structures (G-four-stranded) do exist in living cells in the human body, and that these extraordinary structures may have important biological functions.
